Bausch Health Companies Inc. BHC
8.29 USD -0.11 (-1.31%)
At closeNov 10, 2026, 7:44 PM EST
8.30 +0.01 +0.14%
After hours · Nov 10, 7:44 PM ET
8.16 Day range 8.37
4.33 52-week range 9.04
- YTD
- +19.28%
- 1 year
- +29.53%
News
benzinga.com Bausch Health And Gastroenterology Unit Salix Pharmaceuticals To Present New Data On Cirrhosis Trends And Severe Alcohol-Associated Hepatitis At The Liver Meeting, November 5–9 To present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and
prnewswire.com Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the…
zacks.com BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised…
zacks.com Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year? Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.
benzinga.com Jefferies Maintains Hold on Bausch Health Companies, Raises Price Target to $8 Jefferies analyst Young Li maintains Bausch Health Companies (NYSE:BHC) with a Hold and raises the price target from $6.5 to $8.
benzinga.com RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10 RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and raises the price target from $9 to $10.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
zacks.com BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
benzinga.com Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
seekingalpha.com Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO…
zacks.com Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.
marketbeat.com What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by…
benzinga.com Bausch Health Companies Q3 2026 Earnings Call Transcript Bausch Health Companies (NYSE:BHC) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6…
benzinga.com Bausch Health Companies Announces $50M Buyback Plan Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares…
prnewswire.com Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027 LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of…
prnewswire.com Bausch Health Announces US$50 Million Share Repurchase Program LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company…- benzinga.com Bausch Health Companies Raises FY2026 Sales Guidance from $10.790B-$11.040B to $10.975B-$11.175B vs $10.927B Est Bausch Health Companies (NYSE:BHC) raises FY2026 sales outlook from $10.790 billion-$11.040 billion to $10.975 billion-$11.175 billion vs $10.927 billion estimate.
benzinga.com Bausch Health Companies Q3 Adj. EPS $1.77 Beats $1.29 Estimate, Sales $2.941B Beat $2.757B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.29 by 37.21 percent. This is a 52.59 percent increase over earnings…
prnewswire.com BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million…
zacks.com BHC Q3 Earnings Preview: Here's What You Should Know Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
defenseworld.net Analyzing Bausch Health Cos (NYSE:BHC) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Bausch Health Cos (NYSE: BHC - Get Free Report) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) are both healthcare companies, but which is the superior investment?…- benzinga.com Bausch Health Canada Announces Expanded Public Reimbursement For PrOKEDI 75 Mg And 100 Mg, With Coverage Now Available In Seven Provinces And Multiple Federal Drug Plans PrOKEDI® is now listed in Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia and Prince Edward Island, as well as through federal drug plans administered by the Non-Insured Health…
defenseworld.net Bausch Health Cos Inc. (NYSE:BHC) Stock Has Consensus Target Price of $8.00 Shares of Bausch Health Cos Inc. (NYSE: BHC - Get Free Report) have received a consensus rating of "Hold" from the seven brokerages that are covering the firm, Marketbeat.com reports. One research…
benzinga.com Why Is Bausch + Lomb Stock Falling Monday? Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
defenseworld.net Bausch Health Cos (NYSE:BHC) Shares Gap Up – What’s Next? Bausch Health Cos Inc. (NYSE: BHC - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $6.04, but opened at $6.27. Bausch Health Cos shares last…
prnewswire.com Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter…- benzinga.com Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1…
businesswire.com Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today…
prnewswire.com Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch…
zacks.com 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
zacks.com Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.
benzinga.com Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
benzinga.com This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap…
benzinga.com Bausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est Bausch Health Companies (TSX:BHC) raises FY2026 sales outlook from $10.670 billion-$10.920 billion to $10.790 billion-$11.040 billion vs $10.773 billion estimate.- benzinga.com Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.06 Estimate, Sales $2.852B Beat $2.679B Estimate Bausch Health Companies (TSX:BHC) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.06 by 17.76 percent. This is a 38.46 percent increase over earnings of…
- benzinga.com Bausch Health Announces Quebec Provincial Listing Of Prokedi For Treatment Of Schizophrenia In Adults PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults. According to the Canadian product monograph, PrOKEDI® achieves clinically…
- benzinga.com Bausch Health, Canada, Completes Negotiations With pan-Canadian Pharmaceutical Alliance Resulting In LOI For PrOKEDI 75mg And 100mg, Long-Acting Injectable Antipsychotic Agent For Schizophrenia Treatment Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance…
- benzinga.com Bausch Health And Solta Medical Announce Thermage Awarded AAA Well-Known Trademark Certification By China Trademark Association Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May…
benzinga.com Bausch Health Companies Raises FY2026 Sales Guidance from $10.625B-$10.875B to $10.670B-$10.920B vs $10.595B Est Bausch Health Companies (NYSE:BHC) raises FY2026 sales outlook from $10.625 billion-$10.875 billion to $10.670 billion-$10.920 billion vs $10.595 billion estimate.- benzinga.com Bausch Health Companies Q1 Adj. EPS $0.78 Beats $0.69 Estimate, Sales $2.524B Beat $2.409B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.69 by 13.04 percent. This is a 27.87 percent increase over earnings…
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $9 RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and lowers the price target from $10 to $9.
benzinga.com Barclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7 Barclays analyst Glen Santangelo maintains Bausch Health Companies (NYSE:BHC) with a Equal-Weight and lowers the price target from $8 to $7.- benzinga.com Bausch Health Companies Sees FY2026 Sales $10.625B-$10.875B vs $10.595B Est Bausch Health Companies (NYSE:BHC) sees FY2026 sales of $10.625 billion-$10.875 billion vs $10.595 billion analyst estimate.
benzinga.com Insights into Bausch Health Companies Q4 Earnings 
benzinga.com Bausch Health Companies Q4 Earnings Report: What Investors Need to Know - benzinga.com Bausch Health Companies Q4 Adj. EPS $1.10 Misses $1.26 Estimate, Sales $2.796B Beat $2.696B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.10 per share which missed the analyst consensus estimate of $1.26 by 12.97 percent. This is a 5.98 percent decrease over earnings…